Dr. Michael W. Lattanzi
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- New York University School of Medicine (2016)
- Years since graduation
- 10
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 573
Licensed in Texas since 2022, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Medical school: New York University School of Medicine
- 2016Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license T5155 (first issued 2022; active) -
Medical Oncology Physician
NC license 2022-01073 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St David's Medical Center Austin, TX
- Ascension Seton Medical Center Austin Austin, TX
- North Austin Medical Center Austin, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 573
- Services billed
- 155,189
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 18,180 | 16 |
| Injection, pembrolizumab, 1 mg | 17,200 | 33 |
| Injection, paclitaxel, 1 mg | 14,103 | 26 |
| Injection, fosaprepitant, 1 mg | 13,650 | 44 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 10,150 | 87 |
| Injection, iron sucrose, 1 mg | 9,600 | 28 |
| Injection, aprepitant, 1 mg | 2,730 | 13 |
| Injection, denosumab, 1 mg | 1,980 | 14 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,759 | 83 |
| Injection, palonosetron hcl, 25 mcg | 1,280 | 65 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Austin, TX | 85 |
| Potassium Chloride Other prescribers in Austin, TX | 65 |
| Eliquis (apixaban) Other prescribers in Austin, TX | 58 |
| Oxycodone Hcl Other prescribers in Austin, TX | 58 |
| Ondansetron Odt (ondansetron) Other prescribers in Austin, TX | 57 |
| Prochlorperazine Maleate Other prescribers in Austin, TX | 40 |
| Abiraterone Acetate | 38 |
| Diphenoxylate-Atropine (diphenoxylate hcl/atropine) Other prescribers in Austin, TX | 37 |
| Dexamethasone Other prescribers in Austin, TX | 36 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Austin, TX | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 18 companies reported 92 payments worth $60,164 in total to this clinician.
| Exelixis Inc. | $12,953 |
|---|---|
| Janssen Biotech, Inc. | $12,021 |
| Pfizer Inc. | $9,401 |
| Astellas Pharma US Inc | $8,651 |
| AstraZeneca Pharmaceuticals LP | $7,136 |
| Aveo Pharmaceuticals, Inc. | $5,701 |
| Merck Sharp & Dohme LLC | $2,833 |
| Janssen Scientific Affairs, LLC | $1,125 |
| Compensation for services other than consulting (speaking, faculty) | $22,695 |
|---|---|
| Consulting Fee | $20,718 |
| Travel and Lodging | $8,037 |
| Speaking at a medical education program | $6,825 |
| Food and Beverage | $1,867 |
| Education | $23.10 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Jun 18, 2025 | Consulting Fee PADCEV · ONCOLOGY | $4,625 |
| Aveo Pharmaceuticals, Inc. Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology Company’s descriptionSpeaker Compensation | $4,095 |
| Astellas Pharma US Inc Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) Xtandi · Oncology | $3,600 |
| Pfizer Inc. Aug 22, 2025 | Consulting Fee TALZENNA · ONCOLOGY | $3,500 |
| AstraZeneca Pharmaceuticals LP Dec 16, 2025 | Consulting Fee Truqap · Oncology | $3,350 |
| AstraZeneca Pharmaceuticals LP Oct 1, 2025 | Consulting Fee IMFINZI · Oncology | $3,350 |
| Janssen Biotech, Inc. Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $3,300 |
| Janssen Biotech, Inc. Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $2,860 |
| Janssen Biotech, Inc. Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $2,860 |
| Exelixis Inc. Aug 12, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $2,835 |
All 46 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Dec 16, 2025 | Consulting Fee Truqap · Oncology | $3,350 |
| Astellas Pharma US Inc Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) Xtandi · Oncology | $3,600 |
| Astellas Pharma US Inc Nov 12, 2025 | Travel and Lodging Xtandi · Oncology · travel to The Woodlands, TX | $1,218 |
| Astellas Pharma US Inc Nov 11, 2025 | Compensation for services other than consulting (speaking, faculty) Padcev · Oncology | $2,750 |
| Janssen Biotech, Inc. Nov 11, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $440 |
| Exelixis Inc. Oct 21, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $2,100 |
| Exelixis Inc. Oct 13, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to San Antonio, TX · in-kind | $859 |
| AstraZeneca Pharmaceuticals LP Oct 1, 2025 | Consulting Fee IMFINZI · Oncology | $3,350 |
| Exelixis Inc. Oct 1, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,680 |
| Aveo Pharmaceuticals, Inc. Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology Company’s descriptionSpeaker Compensation | $455 |
| Pfizer Inc. Aug 22, 2025 | Consulting Fee TALZENNA · ONCOLOGY | $3,500 |
| Janssen Biotech, Inc. Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $2,860 |
| Merck Sharp & Dohme LLC Aug 20, 2025 | Consulting FeeCompany’s descriptionPayment made to Third Party Organization not to Physician. | $1,830 |
| Janssen Biotech, Inc. Aug 20, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $880 |
| Merck Sharp & Dohme LLC Aug 20, 2025 | Travel and Lodging travel to Austin, TX Company’s descriptionPayment made to Third Party Organization not to Physician. | $150 |
| Exelixis Inc. Aug 12, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $2,835 |
| Aveo Pharmaceuticals, Inc. Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology Company’s descriptionSpeaker Compensation | $4,095 |
| Janssen Biotech, Inc. Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $3,300 |
| Janssen Biotech, Inc. Jul 31, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Grapevine, TX · in-kind | $619 |
| Exelixis Inc. Jul 30, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Westminster, CO · in-kind | $284 |
| Exelixis Inc. Jul 30, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Westminster, CO · in-kind | $284 |
| Exelixis Inc. Jul 30, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Westminster, CO · in-kind | $284 |
| Exelixis Inc. Jul 26, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Westminster, CO · in-kind | $188 |
| Exelixis Inc. Jul 26, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Westminster, CO · in-kind | $70.00 |
| Exelixis Inc. Jul 26, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Westminster, CO · in-kind | $65.00 |
| Exelixis Inc. Jul 26, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Westminster, CO · in-kind | $45.00 |
| Exelixis Inc. Jul 25, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Westminster, CO · in-kind | $767 |
| Aveo Pharmaceuticals, Inc. Jul 16, 2025 | Travel and Lodging FOTIVDA · Oncology · travel to Denison, TX · in-kind Company’s descriptionGround Transportation | $593 |
| Aveo Pharmaceuticals, Inc. Jul 16, 2025 | Travel and Lodging FOTIVDA · Oncology · travel to Denison, TX · in-kind Company’s descriptionAirfare | $507 |
| Astellas Pharma US Inc Jul 11, 2025 | Compensation for services other than consulting (speaking, faculty) Padcev · Oncology | $825 |
| Exelixis Inc. Jul 10, 2025 | Speaking at a medical education program CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $210 |
| Janssen Biotech, Inc. Jul 1, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Grapevine, TX · in-kind | $5.50 |
| Janssen Biotech, Inc. Jun 27, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Grapevine, TX · in-kind | $127 |
| Janssen Biotech, Inc. Jun 26, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Grapevine, TX · in-kind | $19.50 |
| Janssen Biotech, Inc. Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $2,860 |
| Pfizer Inc. Jun 18, 2025 | Consulting Fee PADCEV · ONCOLOGY | $4,625 |
| Exelixis Inc. Jun 2, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Westminster, CO · in-kind | $676 |
| Janssen Biotech, Inc. May 21, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $330 |
| AstraZeneca Pharmaceuticals LP Apr 30, 2025 | Education in-kind Company’s descriptionJournal Article | $23.10 |
| Exelixis Inc. Apr 18, 2025 | Consulting Fee CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $2,100 |
| Merck Sharp & Dohme LLC Apr 14, 2025 | Consulting FeeCompany’s descriptionPayment made to Third Party Organization not to Physician. | $228 |
| AstraZeneca Pharmaceuticals LP Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $300 |
| Pfizer Inc. Apr 6, 2025 | Travel and Lodging TALZENNA · ONCOLOGY · travel to Austin, TX · in-kind | $359 |
| Pfizer Inc. Mar 22, 2025 | Travel and Lodging PADCEV · ONCOLOGY · travel to Denver, CO · in-kind | $917 |
| Merck Sharp & Dohme LLC Feb 5, 2025 | Consulting FeeCompany’s descriptionPayment made to Third Party Organization not to Physician. | $610 |
| Janssen Scientific Affairs, LLC Jan 14, 2025 | Consulting Fee ERLEADA · Oncology | $1,125 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $89,252 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterio…
Janssen Research & Development, LLC - Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Daiichi Sankyo Inc. · Recruiting · NCT07129993 - Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
AbbVie Inc. · Active, not recruiting · NCT06632951 - A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for…
AstraZeneca Pharmaceuticals LP - A Phase II, Open-label, Multi-Center, Randomized Study Comparing the Combination of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) and Androgen Receptor Pathway Inhibitor (ARPI) vs. Lutetium (177Lu) Vipivotide Tetrax…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.